GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicamen Biotech Ltd (NSE:MEDICAMEQ) » Definitions » EBIT

Medicamen Biotech (NSE:MEDICAMEQ) EBIT : ₹144 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Medicamen Biotech EBIT?

Medicamen Biotech's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ₹46 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹144 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medicamen Biotech's annualized ROC % for the quarter that ended in Dec. 2024 was 5.81%. Medicamen Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 10.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medicamen Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 2.32%.


Medicamen Biotech EBIT Historical Data

The historical data trend for Medicamen Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicamen Biotech EBIT Chart

Medicamen Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 185.49 174.58 194.95 199.68 174.73

Medicamen Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.19 45.43 22.62 29.97 46.37

Competitive Comparison of Medicamen Biotech's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicamen Biotech's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicamen Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medicamen Biotech's EV-to-EBIT falls into.



Medicamen Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹144 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicamen Biotech  (NSE:MEDICAMEQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medicamen Biotech's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=179.828 * ( 1 - 24.63% )/( (2331.375 + 0)/ 1 )
=135.5363636/2331.375
=5.81 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2885.114 - 489.589 - ( 64.15 - max(0, 687.969 - 1567.685+64.15))
=2331.375

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Medicamen Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=185.46/( ( (877.955 + max(960.818, 0)) + (0 + max(0, 0)) )/ 1 )
=185.46/( ( 1838.773 + 0 )/ 1 )
=185.46/1838.773
=10.09 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(566.444 + 599.697 + 294.961) - (489.589 + 0 + 10.695)
=960.818

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medicamen Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=144.384/6213.205
=2.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicamen Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Medicamen Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicamen Biotech Business Description

Traded in Other Exchanges
Address
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, IND, 110019
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. The company generates revenue from the sale of pharmaceutical products.

Medicamen Biotech Headlines

No Headlines